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ABSTRACT
Viruses use alternative splicing to produce a broad
series of proteins from small genomes by utilizing
the cellular splicing machinery. Since viruses use
cellular RNA binding proteins for viral RNA
processing, it is presumable that the splicing of
cellular pre-mRNAs is affected by viral infection.
Here, we showed that herpes simplex virus type 2
(HSV-2) modifies the expression of promyelocytic
leukemia (PML) isoforms by altering pre-mRNA
splicing. Using a newly developed virus-sensitive
splicing reporter, we identified the viral protein
ICP27 as an alternative splicing regulator of PML
isoforms. ICP27 was found to bind preferentially to
PML pre-mRNA and directly inhibit the removal of
PML intron 7a in vitro. Moreover, we demonstrated
that ICP27 functions as a splicing silencer at the 3’
splice site of the PML intron 7a. The switching of
PML isoform from PML-II to PML-V as induced by
ICP27 affected HSV-2 replication, suggesting that
the viral protein modulates the splicing code of
cellular pre-mRNA(s) governing virus propagation.
INTRODUCTION
As many as two-third of human genes produce two or
more isoforms from one gene by alternative pre-mRNA
splicing (1,2). Alternative splicing is strictly regulated
across cell and tissue types, sex determinations, signal-
regulated changes and developmental stages to provide a
variety of gene functions depending on the situation (3,4).
Alternative splicing also contributes to viral proteomic
diversity (5). In the case of human immunodeﬁciency
virus type 1, primary RNA transcripts are alternatively
spliced to generate more than 40 diﬀerent mRNAs (6).
As viral RNA processing is often catalyzed by cellular
RNA-binding proteins such as serine–arginine rich (SR)
proteins (7,8), virus infection sometimes aﬀects the host
RNA processing factor (9,10). However, the eﬀects of
viral proteins on cellular mRNA splicing have poorly
been investigated.
Herpes simplex virus type 2 (HSV-2) is a nuclear
replicating DNA virus and a highly adapted human
pathogen with rapid lytic replication cycle. When the
viral capsid makes its entry into the host cell nucleus,
HSV-2 genome DNA localizes to discrete nuclear foci
called promyelocytic leukemia nuclear bodies (PML-
NBs), also known as nuclear domain 10 (ND10) or
PML oncogenic domain (POD) (11). PML was originally
characterized as part of a fusion protein with RARa
cloned from acute PML patients (12–14). PML is
expressed in all normal tissues as well as tumor cell
lines; however, its expression is reduced in some
progressed tumors (15). The size of PML-NBs varies
from 0.2 to 1mm, and their frequency depends on cell
type, cycle, and status (16–19). PML-NBs consist of
many kinds of proteins involved in various functions
(20,21), and are implicated in various cell processes,
including apoptosis, DNA repair, transcription,
senescence, cell proliferation, signal transduction and
viral pathogenicity (19,20,22–29). PML-NBs have been
thought to contribute to intrinsic antiviral defense on
the interferon pathway (30). However, recent reports
have indicated that PML-NBs provide scaﬀolds for
DNA viruses and promote eﬃcient viral propagation
(11,24,31). Thus, a simple model is not suﬃcient to accom-
modate all accumulated evidence.
The human PML gene consists of nine major exons,
and several alternatively spliced PML transcripts lead to
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(32,33), as shown in Figure 1A. PML exon 1 to exon 4,
which are common to all isoforms, are translated into the
tripartite motif (TRIM) including the RING ﬁnger, B-box
and coiled-coil domain. On the other hand, PML exon
5 to exon 9 can be alternatively spliced, generating mul-
tiple PML isoforms such as PML-I containing the putative
exonuclease III domain (34). Furthermore, PML exon 6
contains the nuclear localization signal, and can be
excluded for the expression of the cytoplasmic PML-VII
isoform, which is essential for TGF-b signaling (27,33).
Thus, the PML gene utilizes alternative pre-mRNA
splicing for the functional diversity of its own protein
products.
In this study, we hypothesized that the conﬂicting host–
virus interactions at PML-NBs may reﬂect the diﬀerential
functions of PML isoforms. Consequently, we found that
the expression of PML splicing isoforms was switched
during HSV-2 infection by alternative splicing. Our
group has recently developed a splicing reporter capable
of visualization of alternative splicing events in vivo and
has also identiﬁed novel trans-acting factors (35,36). Here,
we newly developed a virus-sensitive splicing reporter
whose ﬂuorescent protein expression is changed in HSV-
2-infected cells, and we identiﬁed infected cell protein 27
(ICP27) as an alternative splicing regulator. ICP27 prefer-
entially interacted with PML pre-mRNA and suppressed
intron 7a removal presumably by modulating 30 splice site
(ss) recognition of the cellular trans-acting factor.
MATERIALS AND METHODS
Construction of plasmids
We constructed the reporter minigene PML E6-7b by
amplifying the PML genomic DNA fragments spanning
from exon 6 to exon 7b and cloning to a pcDNA3 vector
(Invitrogen). Constructs expressing myc-tagged HSV-2
cDNAs and Flag-tagged ICP27 were prepared by
inserting PCR products from the cDNA of HSV-2-
infected HEK293 cells into the pcDNA3 vector. A con-
struct for the preparation of the T-REx293/Flag-ICP27
stable cell line was prepared by inserting PCR
products from the cDNA of HSV-2-infected HEK293
cells into the pcDNA5/FRT vector in accordance with
the manufacturer’s protocol (Invitrogen). Constructs
expressing RFP-PML-II and RFP-PML-V were prepared
by inserting PCR products from the cDNA of HEK293
cells into the pmRFP-C1 vector (Clontech). The
constructs of ICP27 mutant M15, PML-small interference
(siRNA)-resistant mutants, PML intron 7a-deletion
mutant d1 and PML 30 ss mutants m1-m4 were made
using a QuikChange II XL kit (Stratagene). The cloning
primers are shown in Supplementary Table S1.
RT–PCR
RNA was isolated from intact, HSV-2-infected cells, and
transfected cells with sepasol RNA I (Nacalai). For
reverse transcription, 500ng of total RNA from each
sample was incubated with oligo (dT)20 and Superscript
II reverse transcriptase (Invitrogen). PCR products were
analyzed by 2% agarose gel electrophoresis, followed by
ethidium bromide staining. As shown in Figure 1C, semi-
quantitative PCR products were analyzed using the 2100
Bioanalyzer (Agilent Technologies) following the protocol
stated in the manuals. The PCR primers are shown in
Supplementary Table S2.
Viruses and antibodies
HSV-2 strain G [HSV-2 (G)] and Venus-HSV-2 strain
YK381 were used at multiplicities of infection (MOI)
based on their plaque-forming unit titers in Vero cells.
Anti-Flag M2 antibody, anti-c-myc antibody, anti-ICP27
(8.F.137B) and Pan-PML antibody (H-238) were
purchased from Sigma, Nacalai, Abcam and Santa Cruz,
respectively. PML-II- and PML-V-speciﬁc sera were a
kind gift from H. de The (18).
Construction of YK381 expressing Venus fluorescent
protein
In pRB5198 (37), a region containing the bidirectional
polyadenylation [poly(A)] signals of HSV-1(F) UL21
and UL22 was cloned into pBluescript II KS(+)
(Stratagene). To construct p26.5-Venus, a SacI-BstEII
fragment of pRB4090 (a kind gift from Dr Bernard
Roizman) containing the promoter region of HSV-1(F)
UL26.5 and a BamHI–EcoRI fragment of Venus/pCS2
(38) containing the entire open reading frame of Venus
were subsequently cloned into pRB5198. The resultant
plasmid contains a Venus expression cassette driven by
the UL26.5 promoter. The BamHI fragment, 8.2kb,
encoding UL1 to a part of UL5 of the HSV-2 186 viral
genome was cloned into pBluescript II KS(+) to yield
p2UL3-4. p2UL3-4pac, in which the PacI site was
introduced into the region between poly (A) signals for
HSV-2 186 UL3 and UL4 genes, was generated by site-
speciﬁc mutagenesis. p26.5-Venus in 2UL3-4 was
constructed by cloning the SacI–KpnI fragment of
p26.5-Venus containing the Venus expression cassette
into the PacI site of p2UL3-4pac and used as a transfer
plasmid for the generation of a recombinant virus YK381
expressing Venus ﬂuorescent protein driven by the UL26.5
promoter, as described previously (38). YK381 exhibits an
identical phenotype to wild-type HSV-2 186 in cell
cultures and mouse models (T.M. and Y.K., unpublished
observation).
Virus infection
HeLa and HEK293 cells were seeded into 6-well plates,
and cells reaching 100% conﬂuence were infected with
HSV-2(G), as stated in the relevant ﬁgure legend. To
examine the role of PML in HSV-2 replication, HeLa
cells were transfected with PML siRNA for 48h before
the viral infection. For the PML splicing isoform rescue
experiments shown in Figure 8F, HeLa cells were
transfected with PML siRNA and then with plasmids
containing either the siRNA-resistant RFP-PML-II
mutant or RFP-PML-V mutant on the next day. HeLa
cells were infected with HSV-2(G) for 24h after plasmid
transfection. The production of infectious HSV-2 was
assessed by plaque assay in Vero cells (39). Vero cells
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infected with a diluted whole-cell extract of HSV-2(G)-
infected cells. The whole cell extract was prepared by
three repeats of freeze-thaw disruption of HSV-2(G)-
infected cells. After 1h adsorption, the inoculum was
removed and the cell monolayer was overlaid with
Dulbecco’s modiﬁed Eagle medium (DMEM) containing
1% fetal calf serum (FCS) and 0.16mg/ml pooled human
immunoglobulin (Sigma). The overlaid medium was
removed after 2 days of infection, and the infected cell
monolayer was ﬁxed and stained with methanol and
0.1% crystal violet, respectively.
Confocal immunofluorescence microscopy
Twenty-four hours after the transfection, cells on 15-mm
glass coverslips were ﬁxed with 4% paraformaldehyde for
10min, permeabilized with 0.5% Triton X-100 for 20min,
blocked with the blocking solution (0.2% Gelatin, 1%
BSA, 0.05% Tween 20 in PBS) for 30min and reacted
with a diluted primary antibody in the blocking solution
for 12h at 48C. After incubation, cells were washed exten-
sively with a washing solution [0.05% Tween 20 in PBS
(pH 8.0)], incubated for 2h at room temperature with the
appropriate secondary antibody diluted in the blocking
solution, and then washed three times with the washing
solution. The cells were analyzed under a confocal micro-
scope (Olympus; FV1000; confocal aperture, 300mm)
through a PLAPO 60  NA:1.40 objective lens. ICP27
and PML-NB signals were collected sequentially by exci-
tation with a 488nm laser and a 543nm laser, respectively.
Transfection of plasmids and siRNAs
HeLa, HEK293, and Vero cells were grown in DMEM
(Nacalai) supplemented with 10% heat-inactivated FCS,
and then maintained by the standard protocol. HeLa and
HEK293 cells were transfected with GeneJuice (Roche) or
Lipofectamine 2000 (Invitrogen) and TransIT293 (Mirus),
respectively. All plasmids used for transfection were
prepared using a Maxiprep kit (Biogene). HEK293 cells
were grown in a monolayer in 6-well plates, and then
co-transfected with 500ng per well of a reporter plasmid
and 500ng of either myc-vector or plasmids expressing
myc-tagged HSV-2 proteins.
siRNA transfection was performed in 12-well plates by
transfecting HeLa cells with 20pmol per well of siRNAs
against either the LacZ reporter (Invitrogen) or PML
(Invitrogen, UCUUGGAUACAGCUGCAUCUUUC
CC), using Lipofectamine RNAiMAX (Invitrogen).
In vitro splicing reaction
The PCR products of human T7-PML wt (exon 7, 53nt;
intron 7a, 641nt; and exon 7b, 213nt) and T7-PML d1
(exon 7, 53nt; intron 7a, 257nt; and exon 7b, 213nt) were
used as the DNA template for T7 transcription.
Pre-mRNA substrates were m7GpppG-capped and
32P-labeled by in vitro transcription. In vitro splicing
reactions were performed in 20ml volumes at 308C
under the conditions described by Krainer et al. (40). As
shown in Figure 6E, highly puriﬁed Flag-ICP27
was added in the reaction system. After the reaction,
RNA was subjected to denaturing PAGE analysis and
autoradiography.
RNA immunoprecipitation
Nuclear extracts were prepared from HEK293 cells
transfected with plasmids expressing Flag alone, Flag-
ICP27 wild-type and M15.
32P-labeled PML exon 7-7b,
b-globin and d-crystallin RNA were prepared by in vitro
transcription with [a-
32P]UTP and T7 RNA polymerase
(Takara). Gel puriﬁed RNA was incubated for 30min at
308C with each nuclear extract in 20ml of RNA binding
buﬀer [20mM HEPES–KOH (pH 7.9), 100mM KCl, 5%
Glycerol, 1% Triton X-100, 2mM DTT and 0.2mM
PMSF] supplemented with 0.4 U of an RNase inhibitor
(Promega), and immunoprecipitation was then performed
with Flag-M2 antibody. Each RNA was puriﬁed by
the protein removal and ethanol precipitation. The
puriﬁed RNAs were analyzed by denaturing PAGE and
imaging using a phosphoimage analyzer (FLA-3000G;
FUJIFILM).
Preparation of stable transfected T-REx293 cells
T-REx293 cells (the HEK293 cell line expressing a tetra-
cycline repressor obtained from Invitrogen) were grown
following the manufacturer’s protocol in DMEM
(Nacalai) containing 10% heat-inactivated FCS and
10mg/ml blasticidin (Invitrogen). To generate stably
transfected tetracycline inducible cell lines, T-REx293
cells were co-transfected with either pcDNA5-Flag or
pcDNA5-Flag-ICP27. After 48h post-transfection, these
transfected cells were grown in the presence of 0.1mg/ml
hygromycin B following the manufacturer’s protocol
to select stable transfected clones.
RESULTS
HSV-2 infection switches the expression pattern of
PML isoforms
We ﬁrst compared the splicing patterns of PML
transcripts from HeLa cells, with and without HSV-2
infection. Total RNAs of HeLa cells were collected imme-
diately (0h post-infection, 0hpi) and 3h post-infection
(3hpi). The RT–PCR analysis, using the primer sets
indicated in Figure 1A, showed that the amounts
of mRNAs containing PML-I-speciﬁc exon 8-9 and
PML-II-speciﬁc exon 6-7b were reduced in the HSV-2-
infected HeLa cells (Supplementary Figure S1A and
Figure 1B, top, lane 4), whereas the amounts of PML
mRNA containing constitutive exon 1-4 (Supplementary
Figure S1A) and exon 6-7 (Figure 1B. middle, lane 4), and
GAPDH mRNA were much less reduced (Figure 1B,
bottom, lane 4 and Supplementary Figure S1A).
Moreover, we examined other cellular mRNAs
containing constitutive introns (Aly/REF intron 4,
Lamin A/C intron 6), alternative introns (Lamin A/C
introns 9 and 10) and minor introns (P120 intron 6,
HPS1 intron 16) by RT–PCR analysis. The expression
levels and splicing patterns of the mRNAs containing these
introns were not signiﬁcantly changed (Supplementary
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containing PML-V-speciﬁc exon 7-7a-7b was increased
in the HSV-2-infected cells (Figure 1B, top). The quanti-
tative analysis also showed that the ratio of PML splicing
isoforms (PML-V/PML-II) was enhanced by HSV-2 infec-
tion (Figure 1C, 2.9-fold in 3hpi). Consistent with the
reduction in PML-II-speciﬁc exon 7-7b, PML-II foci
recognized by PML-II-speciﬁc antibody were reduced in
the HSV-2-infected cells (Supplementary Figure S2).
These observations indicate that HSV-2 infection changes
the alternative splicing of PML pre-mRNA.
The splicing reporter of PML gene is sensitive to
HSV-2 infection
We have recently succeeded in visualizing the tissue-
speciﬁc regulation of alternative pre-mRNA splicing in
live nematodes by developing a transgenic reporter
system with ﬂuorescent proteins (35). Using this system,
we have identiﬁed three genes as alternative splicing
regulators (35,36). To clarify the HSV-2-mediated regula-
tory mechanism of alternative splicing of the PML pre-
mRNA, we prepared splicing reporter minigene constructs
containing the region from exon 6 to exon 7b of the PML
gene without or with the red ﬂuorescent protein (RFP)
coding region, and named them E6-7b and E6-7b-RFP,
respectively (Figure 2A). The splicing reporter E6-7b-RFP
can express RFP only when intron 7a is spliced out and
the PML-II form is produced. Notably, when we
transfected E6-7b-RFP into HeLa cells, RFP was detected
in the transfected cells. To examine whether or not we can
use E6-7b-RFP as a screening tool of viral splicing
regulators, we observed RFP expression in Venus-HSV-
2-infected cells. As we initially assumed, the RFP
expression was reduced in the Venus-HSV-2-infected
cells in a viral titer-dependent manner (Figure 2B and
Supplementary Figure S3), suggesting that the minigene
reporter reﬂects the splicing alteration induced by HSV-2
infection. To examine whether or not the reduction of
RFP expression was caused by HSV-2 regulated-pre-
mRNA splicing, we performed RT–PCR analysis of
HeLa cells transfected with the E6-7b (Figure 2C, lanes
1 and 2) or E6-7b-RFP (Figure 2C, lanes 3 and 4) reporter
and then infected with HSV-2 at MOI 10 for 3 hours
(Figure 2C, lanes 2 and 4). Regardless of the additional
RFP coding region, the promotion of intron 7a retention
in the HSV-2-infected HEK293 cells was conﬁrmed by
RT–PCR (Figure 2C, lanes 3 and 4). The incomplete
retention of intron 7a by HSV-2 infection might be
caused by the remaining uninfected cells under the experi-
mental condition, as shown in Figure 1B, lanes 4. These
observations indicate that the E6-7b-RFP reporter can be
used as a screening tool of viral splicing regulators.
The viral protein ICP27 switches the splicing pattern
of PML pre-mRNA
To identify viral splicing regulator(s), HSV-2 cDNAs
coding 26 viral nuclear proteins of HSV-2 were
co-transfected with PML E6-7b-RFP into HeLa cells,
Figure 1. Modulation of PML expression by HSV-2 infection. (A) Schematic representation of the PML gene and mRNA species generated by
alternative splicing. The positions of diﬀerent primer sets used for RT-PCR are indicated by colored arrow heads. (B) RT–PCR analysis (28 cycles)
of uninfected (U: lanes 1 and 3) and HSV-2-infected (I: lanes 2 and 4) HeLa cells at MOI 1 (0hpi and 3hpi). GAPDH primers were used as a
control. (C) Graphic representation of the splicing ratios PML-V/PML-II. Green and red box indicate the splicing ratio in HSV-2-infected (I) and
uninfected (U) cells, respectively (n=3).
6518 Nucleic Acids Research, 2009, Vol. 37,No. 19and it was demonstrated that RFP expression was lost
only in the cells transfected with the ICP27 or UL41
expression vector (Figure 3A, panels 3 and 22). Further-
more, the reduction of RFP expression was also checked
by western blot (Supplementary Figure S4). ICP27
overexpession dramatically switched the mRNA expres-
sion pattern of the PML E6-7b reporter from the PML-
II-speciﬁc exon 7-7b form to the PML-V-speciﬁc exon
7-7a-7b form (Figure 3B, top, lane 3), whereas other
viral nuclear proteins such as ICP22 or ICP0 did not
aﬀect the splicing (Figure 3B, top, lanes 4 and 5). Also,
the amounts of expressed viral proteins were almost the
same (Figure 3B, bottom). In contrast to ICP27, the
overexpression of UL41 encoding a viral nuclease (41)
suppressed PML-II-RFP expression owing to the pro-
motion of PML-II-RFP RNA degradation (data not
shown). To investigate whether ICP27 can induce
switching of the endogenous PML splicing isoform, we
transfected myc-tagged ICP27 cDNA and then checked
for endogenous PML transcripts by RT–PCR analysis
using a combination of exon 6-forward and exon
7b-reverse primers. The results showed that the intron
7a retention of endogenous PML transcripts was
promoted in proportion to the amount of transfected
ICP27 cDNA (Figure 3C, top and bottom); however,
ICP27 did not inhibit the removal of other introns in
PML pre-mRNA (Figure 3C, upper middle) or actin
pre-mRNA (Figure 3C, lower middle). The foci in myc-
tagged ICP27-expressing cells that were recognized by
anti-PML-II antibody were decreased (Figure 3D,
center), whereas those recognized by anti-PML-V sera
were increased (Figure 3D, right) compared with
untransfected HeLa cells. Moreover, the endogenous
PML-II mRNA was switched to PML-V mRNA in a
Flag-tagged ICP27 stable expressing cell line (T-REx293/
Flag-ICP27), whose transcription was regulated by tetra-
cycline addition (Figure 3E). However, as far as we have
checked, the removal of the other introns containing the
constitutive introns, alternative intron and minor introns
was not aﬀected by Flag-ICP27 (Supplementary
Figure S1C). These observations indicate that ICP27 pref-
erentially switches the expression of PML isoforms from
PML-II to PML-V.
Interestingly, the foci recognized by anti-Pan-PML
antibody were unchanged or only slightly decreased
(Figure 3D, left). Although PML-I-speciﬁc exon 8-9
transcripts were decreased in HSV-2-infected cells, they
were not changed in ICP27-expressing cells (Supple-
mentary Figure S1A). These results suggest that PML-I
mRNA expression is regulated by other viral factors
other than ICP27 or cellular signal induced proteins (e.g.
interferon stimulating factors) in HSV-2-infected cells.
KH3 domain of ICP27 is required to switch the
PML isoform
As shown in Figure 4A, ICP27 contains deﬁned functional
domains, including a nuclear export signal (NES), the
arginine- and glycine-rich motif (RGG box), the
Figure 2. Visualization of virus-sensitive splicing reporter of the PML gene. (A) Schematic representation of two splicing reporters. The splicing
reporter involving the PML gene from exon 6 to exon 7b with (E6-7b-RFP) or without (E6-7b) the RFP coding region, and mRNAs derived from
the reporter. Predicted ORFs are indicated in red (PML-II-RFP) or gray (PML-V x), and UTRs in dark gray. The positions of diﬀerent primer sets
used for RT–PCR are indicated. This reporter is driven by the CMV promoter. (B) Microscopy analysis of Venus-HSV-2-infected cells. HeLa cells
were infected with Venus-HSV-2 at MOI 0.01. After 3h infection, E6-7b-RFP was transfected into the cells. After 24h infection, RFP expression
was reduced particularly in Venus-HSV-2 infected cells, although RFP was well detected in uninfected cells. Venus-HSV-2 is indicated in green.
(C) RT–PCR analysis of uninfected (U) and infected (I) HeLa cells at MOI 10 (3hpi), into which either E6-7b or E6-7b-RFP constructs were
transfected.
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To identify the ICP27 region required to promote reten-
tion of intron 7a of PML, we prepared a series of ICP27
mutants lacking NES (d1-2), the RGG box (RGG),
and the RGG box plus R2 (RR2) (Figure 4A).
Overexpression of the deletion mutants of ICP27 retained
the promotion activity for intron 7a retention (Figure 4B,
top, lanes 4–6), whereas ICP27 mutant M15 containing
altered residues at 465 and 466 (P465L/G466E) in the
KH3 domain (42) failed to switch the alternative splicing
of PML pre-mRNA (Figure 4B, top, lane 7). Wild-type
ICP27 and the mutants were equally expressed in individ-
ual transfected cells (Figure 4B, bottom), and the foci of
PML-II were unaﬀected by M15 expression (Figure 4C,
Figure 3. Retention of PML intron 7a by ICP27. (A) Microscopy analysis of HeLa cells transfected with the combinations of the E6-7b-RFP
construct and each HSV-2 cDNA performed by detecting RFP signaling (red). DNAs were stained with DAPI (blue). (B) RT–PCR analysis of
HEK293 cells transfected with the combinations of E6-7b constructs and plasmids containing myc-tagged HSV-2 cDNA (B, upper panels). Whole-
cell extracts of HEK293 cells transfected with these plasmids were subjected to western blot analysis for myc-tag (B, bottom). (C) RT–PCR, using the
primers shown in Figure 1A, and western blot analysis of HEK293 cells transfected with 2-fold dilution series of myc-tagged ICP27.
(D) Immunoﬂuorescence of HeLa cells transfected with myc-tagged ICP27. PML-NBs were stained with anti-Pan-PML (left), PML-II speciﬁc
(center) and PML-V speciﬁc (right) sera. Scale bar, 10mm. Yellow arrows indicate ICP27-transfected cells. (E) RT–PCR analysis, using the primers
shown in Figure 1A, and western blot analysis for Flag-tag of T-REx293 expressing Flag-tag peptides and Flag-ICP27.
6520 Nucleic Acids Research, 2009, Vol. 37,No. 19lower panels). These results indicate that the KH3 domain
of ICP27 is critical for the switching of the PML isoform
from PML-II to PML-V.
Since the ICP27 protein of HSV-1 is highly homologous
to that of HSV-2, which we used, we next tested whether
HSV-1 ICP27 protein could also aﬀect the PML splicing
or not. The ICP27 of HSV-1 also promoted the intron
retention of PML splicing (Supplementary Figure S5A,
lane 4). The ICP27 gene is conserved in all members of
the herpesvirus family. The UL69 gene (cytomegalovirus;
CMV), EB2 (or SM) gene (Epstein–Barr virus; EBV) and
ORF57 gene (Kaposi’s sarcoma-associated herpesvirus;
KSHV and the herpesvirus saimiri; HVS) are homologues
of the ICP27 gene of each virus. In addition, the amino
acids PG at 465 and 466 in the KH3 domain of ICP27,
which are essential for splicing regulation of PML pre-
mRNA (Figure 4B), are conserved within herpesviridae
(Supplementary Figure S5B) (43). Furthermore, ICP27
and ORF57 reportedly promote intron retention of viral
RNA (44,45). Taken together, these observations strongly
suggest that ICP27-mediated alternative splicing of PML
pre-mRNA is a common feature in the herpesvirus family.
ICP27 is specifically associated with PML pre-mRNA
To examine whether or not ICP27 preferentially associates
with PML pre-mRNA, we performed RNA immunopre-
cipitation assay. Three pre-mRNAs containing human
PML exon 7 to exon 7b, human b-globin exon 1 to exon
2 and chicken d-crystallin exon 14 to exon 15, which
were synthesized by in vitro transcription and labeled
with [a-
32P] UTP, were mixed with the nuclear extract
from HEK293 cells expressing Flag-tagged ICP27
(Figure 5A). Following incubation, RNAs were immuno-
precipitated with anti-Flag antibody. The results showed
that Flag-ICP27 was co-immunoprecipitated with PML
pre-mRNA more eﬃciently (9.3- to 14.0-fold) than
b-globin and d-crystallin pre-mRNAs (Figure 5B, lane 5
Figure 4. Eﬀects of ICP27 mutants on PML RNA splicing. (A) Schematic representation of the structure of ICP27 mutants. (B) RT–PCR and
western blot analysis of HEK293 cells transfected with either myc-tagged ICP27 wild-type or mutant plasmids. (C) Immunoﬂuorescence of HeLa cells
transfected with either myc-tagged ICP27 wild-type or the M15 plasmid, stained with anti-myc antibody and PML-II speciﬁc sera.
Figure 5. RNA binding speciﬁcity of ICP27. (A) Western blot analysis,
using anti-Flag antibody, of nuclear extract from HEK293 cells
transfected with Flag-vector and Flag-ICP27 wild-type (wt) and M15
expression plasmids. (B) RNA immunoprecipitation. Each
32P-labeled
in vitro transcript was incubated with the nuclear extracts from
HEK293 cells expressing Flag-tag or Flag-tagged ICP27, and then
immunoprecipitated with anti-Flag antibody. (C) Quantitation of
three independent experiments is shown. Error bars represent SDs
(n=3).
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experiment using the nuclear extract from HEK293 cells
expressing Flag-ICP27 mutant M15 demonstrated
that Flag-ICP27 mutant M15 was not co-immunopre-
cipitated with these pre-mRNAs (Figure 5B, lane 6 and
5C, black bars). Moreover, the amounts of Flag-ICP27
wild-type and M15 proteins were almost equally
expressed (Figure 5A), indicating that ICP27 speciﬁcally
associated with PML pre-mRNA, at least among cellular
pre-mRNAs, and that the associations depended on
the KH domains, which were presumably the RNA bind-
ing sites.
ICP27 directly inhibits the removal of PML intron 7a
To examine whether or not ICP27 directly inhibits PML
pre-mRNA splicing, we performed an in vitro splicing
reaction. The DNA template T7-wt containing a T7 pro-
moter and PML exon 7 to exon 7b was prepared by PCR
and used for T7 transcription (Figure 6C). The in vitro
splicing reaction resulted in the T7-wt transcript slightly
generating splicing intermediates (Figure 6D, lanes 1–5),
which led us to modify the T7-wt DNA template. We
prepared the mutant d1 which has deletion in intron 7a,
as described in Figure 6A. Transfection of the d1 con-
struct showed that the PML d1 transcript was eﬃciently
Figure 6. Inhibition of PML pre-mRNA splicing by ICP27. (A) Schematic representation of E6-7b wt and deletion-mutant splicing reporters, d1. The
reporter E6-7b d1 contains a 100-bp fragment downstream of the 50 ss and a 157-bp fragment upstream of the 30 ss of intron 7a. (B) RT–PCR
analysis of HEK293 cells transfected with Flag-vector (lane 1), and the combination of either E6-7b wt (lanes 2 and 4) or d1 (lanes 3 and 5) with
either myc-vector (lanes 2 and 3) or myc-ICP27 (lanes 4 and 5). (C) Schematic representation of three E7-7b DNA templates, T7-wt (exon 7: 53bp;
intron 7a: 641bp; exon 7b: 213bp) and T7-d1 (exon 7: 53bp; intron 7a: 257bp; exon 7b: 213bp), which are driven by the T7 promoter. (D) In vitro
splicing of T7-wt (lanes 1–5) and T7-d1 (lanes 6–10) for the indicated time. The size of the pBR322 MspI-digested DNA marker is indicated on the
right side of the panel. The pre-mRNA, mature mRNA and splicing intermediates are described on both sides of the panel. (E) A 10% SDS–PAGE
and CBB staining of the puriﬁed Flag-ICP27 from the nuclear extract of T-Rex 293 cells expressing Flag-ICP27. (F) Eﬀects of ICP27 on T7-d1
splicing in vitro. Two-fold dilution series (0, 25, 50, 100, 200 and 400ng) of BSA (lanes 1–6) and highly puriﬁed Flag-ICP27 (lanes 7–12) were added
to the in vitro splicing reaction.
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was retained by myc-ICP27, as well as the PML wt tran-
script (Figure 6B, lanes 3 and 5). These results indicate
that the PML d1 mutant can be useful for in vitro splicing
reactions. The in vitro splicing of the T7-d1 transcript
showed that it was more eﬃciently spliced than the
T7-wt transcript (Figure 6D, lanes 6–10). Next, we
examined the eﬀects of ICP27 on PML splicing. Flag-
ICP27 was puriﬁed from T-REx293 cells expressing
Flag-ICP27, and then the highly puriﬁed Flag-ICP27
was added to the in vitro splicing reaction using d1
mutant RNA. The results showed that the productions
of T7-d1 spliced mRNA and intermediates were inhibited
by the addition of puriﬁed Flag-ICP27 in a dose-
dependent manner (Figure 6F, lanes 7–12), but not by
BSA (Figure 6F, lanes 1–6). These results indicate that
ICP27 directly inhibits PML pre-mRNA splicing.
3’ Splice site of intron 7a of PML pre-mRNA is critical
for ICP27-mediated switching
The alternative splicing depends on the utilization of the 50
ss and 30 ss at the end of introns (3). The 50 ss includes a
GU dinucleotide at the intron end encompassed within a
less conserved consensus sequence. At the other end of the
intron, the 30 ss region has conserved a polypyrimidine
tract capable of associating with U2AF65/35, followed
by a terminal AG at the extreme 30-end of the intron
(YYYYYNCAG) (46). In contrast, the 30 ss sequence of
PML intron 7a is a purine-rich sequence (ATTGGAA
AG). To evaluate the involvement of the atypical 30 ss of
intron 7a for the ICP27-mediated switching from PML-II
to PML-V, we mutated the 30 ss region of intron 7a in the
PML E6-7b reporter to match with the 30 ss consensus
sequence (Figure 7A, m1-m4). RT–PCR analysis showed
that the ICP27-induced retention of PML intron 7a was
diminished in proportion to the number of mutated
nucleotides at the 30 ss (Figure 7B, lanes 8–12).
PML splicing isoform II contributes to production
of infectious HSV-2
To examine the diﬀerential roles of PML isoforms in
host-virus interactions, we attempted rescue experiments
with a siRNA-resistant PML isoform in PML pre-
knocked down HeLa cells. We ﬁrst eﬃciently knocked
down all PML isoforms from HeLa cells with siRNA
(siPML4) against PML exon 4. Following 48h of
siRNA transfection, HSV-2 was infected and then HSV-
2 titer was measured by plaque assay (Figure 8A). siPML4
eﬃciently knocked down endogenous PML isoforms
(Figure 8B, lane 2), whereas control siRNA (siLacZ) did
not knock down any of them (Figure 8B, lane 1). Plaque
assay revealed that HSV-2 replication was suppressed by
 80% in the PML-knocked-down HeLa cells (Figure 8C),
consistent with the results of the immunoﬂuorescence ana-
lysis (Supplementary Figure S6). We then transfected
these cells with a plasmid encoding either RFP, RFP-
PML-II or RFP-PML-V with a silent mutation that
makes the PML isoform resistant to siPML4, and there-
after evaluated the plaque-forming activity of the virus
(Figure 8D). The rescue experiment showed that RFP-
PML-II increased the HSV-2 plaque number ( 1.6-fold
RFP), but RFP-PML-V did not (Figure 8F), although
the expression levels of the RFP-PML-II and RFP-
PML-V mRNAs were similar (Figure 8E, lanes 2 and 3).
The result showed that the diﬀerence in the rescue
experiments between only RFP and RFP-PML-II
appeared smaller than the reduction of HSV-2 replication
by the knock-down of all PML isoforms. One pos-
sible explanation is the transfection eﬃciencies of RFP
(43%), RFP-PML-II (33%) and RFP-PML-V (34%)
(Supplementary Figure S7). These observations suggest
that the diﬀerence in HSV-2 plaque number may
become larger if all cells expressed siRNA-resistant PML
isoforms, suggesting that PML-II plays a speciﬁc role in
eﬃcient HSV-2 replication.
DISCUSSION
In this study, we identiﬁed ICP27 as a splicing regulator of
PML pre-mRNA, showing the possibility that the viral
protein switches alternative splicing of speciﬁc cellular
RNA in association with functional alteration.
Selective splicing regulation by ICP27
HSV ICP27 is one of the immediate early (IE) proteins of
HSV and plays an essential role in the expression of viral
late genes (47,48). ICP27 interacts and co-localizes with
cellular splicing factors, such as small nuclear ribo-
nucleoproteins (snRNPs) (49), SR proteins, SR protein
kinase 1 (SRPK1) (50) and spliceosome-associated protein
145 (SAP145) (51), and is suggested to inhibit the splicing
of cellular pre-mRNAs by impairing spliceosomal assem-
bly (50). However, considering that some essential viral
pre-mRNAs such as ICP0 have introns and require splic-
ing, it is less likely that HSV suppresses constitutive
Figure 7. The weak 30 ss essential for ICP27-mediated alternative
splicing of PML pre-mRNA. (A) Scheme of the E6-7b construct
wild-type and a series of point mutations at the 30 ss in PML intron
7a. (B) Results of RT–PCR analysis of HeLa cells transfected with each
E6-7b cis-mutant and myc-tagged ICP27.
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speciﬁcally bound to PML pre-mRNA (Figure 5B, lane 5)
and selectively switched the isoform from PML-II to PML-
V by promoting the retention of PML intron 7a
(Figure 3E). Our results indicate that ICP27 is an alterna-
tive splicing factor, although it does not inhibit all consti-
tutive splicing. Moreover, the observed in vitro splicing
suggested that ICP27 directly suppressed the early stage
of spliceosome assembly on PML intron 7a, because
splicing intermediates (50 exon and lariat-30 exon) were
reduced by ICP27 addition (Figure 6F).
The selectivity of ICP27-dependent regulation may be
related to the relative weakness of the 30 ss of PML intron
7a. PML intron 7a was not retained even in the presence
of ICP27 when we mutated the 30 ss to the consensus
sequence for U2AF65/35 (Figure 7B). Therefore, it is
also relevant to examine whether ICP27 selectively binds
to the 30 ss of PML intron 7a by competing with U2AF65/
35. Sokolowski et al. (52) showed that ICP27 binds to
many diﬀerent viral sequences by yeast three-hybrid
screening of an HSV-1 genomic library; however, the
target RNA sequence of ICP27 remains to be elucidated.
Since the ICP27 homolog contains more cellular targets
than PML pre-mRNA (53), in vitro systematic evolution
of ligands by exponential enrichment (SELEX) and in vivo
UV cross-linking immunoprecipitation (CLIP) are
currently under way in our laboratory to determine the
consensus target sequence of ICP27.
A possible role of ICP27-mediated mRNA export
on alternative splicing
Transfection experiments revealed that ICP27 promoted
the intron 7a retention (Figure 3B, lane 3). Although our
results showed that ICP27 directly inhibited the splicing of
PML intron 7a in vitro (Figure 6F), ICP27-mediated alter-
native splicing modulation is still possible to be explained
by another mechanism, a promotion of pre-mRNA export
by ICP27. It has been shown that ICP27 shuttles between
the nucleus and the cytoplasm in host cells (54,55), and
that ICP27 homologues stimulate the export of viral
mRNAs by interacting with the mRNA export adaptor
REF (56–61). The splicing reaction at the weak ss of
PML intron 7a may take longer time than that at the
consensus ss, and the accelerated mRNA export induced
by ICP27 does not provide suﬃcient time for PML pre-
mRNA to be spliced in the nucleus. These two possibilities
are not mutually exclusive. It will be of interest to inves-
tigate if ICP27 promotes export of pre-mRNAs that
harbor introns with weak 30 ss, such as PML.
The role of ICP27 KH domain on PML
alternative splicing
ICP27 M15 mutant failed to alter the expression of PML
splicing isoform (Figure 4B, lane 7), suggesting that the
KH3 domain is critical for the regulation of splicing.
Therefore, we checked whether other KH domains are
also essential for splicing regulation or not. RT–PCR
analyses indicate that the mutants lacking either the
KH2 domain or the KH3 domain were not able to com-
pletely switch PML splicing isoforms (data not shown).
These results suggest that both the KH2 and the KH3
domains are required for altering the splicing.
Unfortunately, the mutant lacking the KH1 domain was
not expressed enough for the splicing experiment. It is
highly likely that all of three KH domains are required
for the regulation of the splicing.
Figure 8. Diﬀerential function of PML isoforms in relation to HSV-2 infection. (A) Experimental procedure for examining the role of PML in HSV-2
viral production. Knockdown of all endogenous PML splicing variants in HeLa cells was performed using siRNA against PML (siPML4). After 48h
of incubation, HeLa cells were infected with HSV-2 at MOI 0.01 for 24h. RT–PCR analysis (B) and plaque assay (C) were performed to determine
knockdown eﬃciency and viral titer, respectively. (B) RT–PCR analysis, using PML ex3-ex4 primers, of siLacZ- or siPML4-treated HeLa cells. (C)
Production of infectious HSV-2 in either siLacZ- or siPML4-treated HeLa cells as assessed by plaque assay (n=4). (D) Experimental procedure for
the rescue assay of PML splicing variants. After 48h of siRNA treatment, the expression plasmids of either RFP or siRNA-resistant PML II or
PML-V were transfected for 24h. Following 24h of infection with HSV-2 at MOI 0.01, RT–PCR analysis (E) and plaque assay (F) were performed.
(E) RT–PCR analysis of siPML4-treated HeLa cells transfected with the RFP vector, RFP-PML-II siRNA resistant (siR), or RFP-PML-V siR
expression plasmids. Details are described in ‘Materials and Methods’ section. (F) Production of infectious HSV-2 in HeLa cells siPML4-treated and
then transfected with each PML plasmid as assessed by plaque assay (n=4).  P<0.001; n.s., not signiﬁcant.
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PML isoforms have diﬀerential localizations and
functions (32–34). For example, p53 interacts with PML-
IV, but not with PML-III, and thus it was speculated that
p53-PML-IV interaction was required for p53 recruitment
into PML-NBs to modulate cell survival (62). Moreover,
retinoblastoma protein (pRB) interacts more eﬃciently
with PML-IV than with PML-II, suggesting that pRB–
PML-IV interaction plays an important role in the regu-
lation of cell diﬀerentiation and proliferation (63). In
the present study, we showed that PML-II can enhance
HSV-2 proliferation in HeLa cells (Figure 8F). In addition
to HSV-2, adenovirus type 5 E4-ORF3 protein reportedly
rearranges PML-NBs to a track-like structure by
speciﬁcally interacting with PML-II (64,65), suggesting
that PML-II may function as a modulator of the viral
environment. However, as shown in the present study,
HSV-2 infection switches the PML isoform from PML-
II to PML-V. Apparently, this switching reduces the eﬃ-
ciency of viral replication (Figure 8F) and is thus not
favorable to the virus, although it may also contribute
to persistent viral infection by controlling viral replication
rate through a negative feedback mechanism. Another
possibility is that this switching is relevant to host defense
to virus production. Because ICP27 is expressed at early
stage of virus infection, the infected cell may utilize ICP27
as virus antigen to monitor virus infection and then the
cells may try to reduce virus replication rate by producing
PML-V, which results in delay of the expansion of virus
infection to surrounding cells.
The expression of PML isoforms diﬀers in various cell
lines or tissues. For example, PML-I is the dominant form
expressed in the brain but not in the liver (18). However,
the regulation mechanisms of the cell type- or tissue-
speciﬁc alternative splicing of PML pre-mRNA have not
been clariﬁed to date. In this study, using our original
splicing reporter with RFP, we demonstrated that the
viral protein ICP27 regulates the switching of the PML
isoform from PML-II to PML-V by promoting the reten-
tion of PML intron 7a; PML-I, however, was not aﬀected
by ICP27 (Supplementary Figure S1A). The mechanism
underlying the HSV-induced decrease in PML-I remains
to be elucidated. The splicing reporter system used in the
present study may pave the way for identifying the cellular
regulators of PML alternative splicing, along with viral
regulatory proteins.
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